Apellis Pharmaceuticals
Stock Forecast, Prediction & Price Target
Apellis Pharmaceuticals Financial Estimates
Apellis Pharmaceuticals Revenue Estimates
Apellis Pharmaceuticals EBITDA Estimates
Apellis Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $66.56M N/A | $75.42M 13.30% | $396.59M 425.82% | Avg: $1.19B Low: $1.00B High: $1.44B avg. 200.79% | Avg: $1.65B Low: $1.43B High: $2.07B avg. 38.62% | Avg: $1.75B Low: $1.52B High: $2.20B avg. 6.23% | Avg: $1.95B Low: $1.70B High: $2.46B avg. 11.49% |
Net Income
% change YoY
| $-746.35M N/A | $-652.17M 12.61% | $-528.62M 18.94% | Avg: $100.90M Low: $-104.43M High: $485.39M avg. 119.08% | Avg: $385.45M Low: $3.56M High: $797.51M avg. 281.99% | Avg: $525.38M Low: $436.54M High: $700.78M avg. 36.30% | Avg: $640.46M Low: $532.16M High: $854.27M avg. 21.90% |
EBITDA
% change YoY
| $-533.00M N/A | $-584.5M -9.66% | $-495.21M 15.27% | Avg: $-676.51M Low: $-820.20M High: $-570.01M avg. -36.61% | Avg: $-937.78M Low: $-1.17B High: $-815.81M avg. -38.62% | Avg: $-996.25M Low: $-1.25B High: $-866.67M avg. -6.23% | Avg: $-1.11B Low: $-1.39B High: $-966.31M avg. -11.49% |
EPS
% change YoY
| -$8.84 N/A | -$6.15 30.42% | -$4.45 27.64% | Avg: $0.97 Low: -$0.88 High: $4.09 avg. 121.82% | Avg: $3.19 Low: $0.03 High: $6.72 avg. 228.78% | Avg: $4.43 Low: $3.68 High: $5.9 avg. 38.62% | Avg: $5.4 Low: $4.48 High: $7.2 avg. 21.90% |
Operating Expenses
% change YoY
| $597.64M N/A | $664.39M 11.17% | $855.20M 28.71% | Avg: $2.18B Low: $1.83B High: $2.64B avg. 155.13% | Avg: $3.02B Low: $2.63B High: $3.80B avg. 38.62% | Avg: $3.21B Low: $2.79B High: $4.03B avg. 6.23% | Avg: $3.58B Low: $3.11B High: $4.50B avg. 11.49% |
FAQ
What is Apellis Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 114.82% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -104.43M, average is 100.90M and high is 485.39M.
What is Apellis Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 64.28% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $1.00B, average is $1.19B and high is $1.44B.
What is Apellis Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 102.78% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$0.88, average is $0.97 and high is $4.09.
What is the best performing analyst?
In the last twelve months analysts have been covering Apellis Pharmaceuticals stock. The most successful analyst is Douglas Tsao.